Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omacor medication errors

Executive Summary

The Institute of Safe Medication Practices is recommending that the name of Reliant's hypertriglyceridemia therapy Omacor (omega-3-acid ethyl esters) be changed due to similarity with Xanodyne's antifibrinolytic agent Amicar (aminocaproic acid). "Prescriptions for Omacor have just begun to arrive in pharmacies, but we've already heard name-related safety issues. A pharmacist reported an error in which a telephone order of Omacor 1 g B.I.D. was misheard as Amicar 1 g B.I.D.," the Nov. 3 issue of ISMP's Medication Safety Alert! says. Reliant launched Omacor in October, following approval in November 2004 (1"The Pink Sheet" June 6, 2005, p. 9)...

You may also be interested in...



Reliant Omacor Launch Funded Through IPO; Launch Set For Late 2005

Reliant Pharmaceuticals will raise cash through an initial public offering to pay for a sales force expansion for the launch of the triglyercide therapy Omacor

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel